Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lynparza Gets First Mover Advantage In BRCA-Positive Breast Cancer

Executive Summary

AstraZeneca and Merck & Co hope to advance Lynparza quickly in prostate and pancreatic cancers after getting first mover advantage in metastatic breast cancer.


Related Content

Ovarian Cancer Market Snapshot: AstraZeneca's Lynparza Poised To Lead In Niche Space
First-Line Chemo Combo Data Help Merck's Keytruda Power Past Opdivo
AstraZeneca Looks To Deliver On Its Promises In Oncology
Keeping Track: Mylan Wins First US FDA Approval For Neulasta Biosimilar, But Lands A CRL For Insulin Glargine; Genentech Nabs Broad Full Approval For Venclexta, PV Indication For Rituxan
As A New Rival Approaches, PARP Makers Look To Carve Out Their Niche
Encouraging Survival Data For Lynparza in Metastatic Breast Cancer
Deal Watch: Fresenius Buyout Of Akorn Potentially Threatened By Data Integrity Issues
Think Positive: Clovis Confident Of CHMP Okay For Rubraca
Pharma Q4 Results Preview: Pfizer, Merck, Roche, Amgen, Novo, Lilly, AstraZeneca
A Whopper Of A Deal: AZ Hands Half Of Lynparza To Merck


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts